Google DeepMind unveils AlphaGenome 2 for cell-type-specific DNA variant prediction
Google DeepMind announced AlphaGenome 2, a conditional DNA sequence model that predicts how genetic variants affect gene regulation in specific human cell types and states, rather than broad tissue averages.
Source-based brief · Editor review not recorded · See checks and limits ↓
One primary source; other links are context, not independent corroboration.
- Primary sourcedeepmind.google
- Discovery linkX
- Linked in sourceRead the paper
- Linked in sourceAlphaGenome
- Linked in sourceAlphaGenome Atlas
- Linked in sourcelandmark study
- Linked in sourceform
- Linked in sourcecommunity forum.
Grok Bot submitted the link. AINewsIQ fetched the primary source and prepared a source-based brief automatically. An editor has not reviewed the story; social attention and the brief do not independently verify its claims.
Open full article view →- Linked article+30
- Fetched source page+30
- No editor link review+0
- Original non-discussion link+5
This measures the stored source trail and editorial steps. It does not certify accuracy, peer review, or independent corroboration. Popularity adds no points.
View full scoring →Read the scoring rubric →What the source says
Google DeepMind announced AlphaGenome 2, a conditional DNA sequence model that predicts how genetic variants affect gene regulation in specific human cell types and states, rather than broad tissue averages. The model was trained on over 107 million single-cell profiles across 68 tissues. It can also generalize to new single-cell data without retraining and impute missing experimental readouts. The post reports improved variant recall on the TenK10K immune cell dataset. The model is available for non-commercial research via API and in private preview for commercial use.
Claim explorer
Attribution, source and conditionsSource-stated points from the stored brief. Claim-level assessments have not been recorded.
Performance figures are the developers' own reported results from their blog post; source claims not independently checked.
This connects a source, an attributed statement and its qualifications. It does not establish that the claim is correct.
Questions worth asking
Open questions for further reportingWhat remains unconfirmed?
Performance figures are the developers' own reported results from their blog post; source claims not independently checked.
What material was available for this brief?
The recorded brief basis is fetched source page. These points are AINewsIQ paraphrases, not quotations or independent confirmations.
AlphaGenome 2 is a conditional model that predicts DNA effects for one tissue, cell type, or state at a time.
Source: deepmind.google ↗Stored source-based brief · key point 1 · AINewsIQ paraphraseOn the TenK10K dataset, it identified about 30% of causal variants versus 16% for the original AlphaGenome fine-tuned on single-cell data.
Source: deepmind.google ↗Stored source-based brief · key point 2 · AINewsIQ paraphraseIt can predict variant effects in newly profiled cell states from a small single-cell sample without retraining.
Source: deepmind.google ↗Stored source-based brief · key point 3 · AINewsIQ paraphraseLimits from the stored brief
Performance figures are the developers' own reported results from their blog post; source claims not independently checked.
This is a source-based abstract, not independent validation of the source's claims.
Evidence & sources
These links show where the signal came from and what the source page linked to. A linked page is context, not independent corroboration.
Related archive coverage
These relationships record a citation or topic overlap, not confirmation of the finding.
Grok Bot submitted the link. AINewsIQ fetched the primary source and prepared a source-based brief automatically. An editor has not reviewed the story; social attention and the brief do not independently verify its claims.
These are Grok Bot discovery notes. AINewsIQ prepared a brief from available source material. The bot's rationale, linked posts, authors, and stances have not been independently verified.
DeepMind's Nov 11 official X post and its blog (URL on X) introduce AlphaGenome 2 for cell-type-specific DNA variant effects; research claims are DeepMind's, not a diagnostic product; primary page not fetched by Grokkie; primary page date unverified; server check pending.
Performance figures are the developers' own reported results from their blog post; source claims not independently checked.
Engagement counts, when shown, are observed snapshots. They do not establish accuracy or corroboration.
- x post ↗ · 2,934 likes, 455 reposts, 261 replies, 243 quotes · observed 11/12/2026, 10:54:10 PM
- Related post ↗
Timeline & updates
- Signal dated by source or discovery feed
This timestamp places the signal in the radar. It may be the discovery post date rather than the primary page's first publication date.
- Shared brief stored
AINewsIQ prepared one abstract from fetched source page.
Brief history · 1 retained version
These are changes to AINewsIQ’s own publication. Earlier history is unavailable unless recorded here. Complete retained versions are available to the editor.
- Version 1 · published
Source-based brief stored or updated. This does not establish that the publisher changed its page.
Automated record
Source observations · 1 recent captures
A changed capture means the extracted text differed. It can reflect page furniture or extraction changes; it does not establish a substantive correction. Source captures remain private.
Retained capture; no earlier comparison available.
New engagement snapshots do not mean the source itself changed. Source observations and AINewsIQ brief revisions are separate records.
Why this may matter
Linking disease-associated genetic variants to the specific cell types where they act could help researchers prioritize candidate variants and experiments, though its practical value for discovery depends on validation beyond these reported benchmarks.
Limits and open questions
Performance figures are the developers' own reported results from their blog post; source claims not independently checked.
Organization-specific financial, security, and operational effects require the organization's own context and review.

Join the discussion
Have a different perspective or a question about the evidence? Discussion is free with a verified email account. Every comment is reviewed before publication.
No published comments yet.
New commenters: 2 submissions per 24 hours, at least 5 minutes apart, until 3 are approved. Discussion guidelines and moderation →